Irene Schiavetti, Alessio Signori, Angela Albanese, Jessica Frau, Eleonora Cocco, Lorena Lorefice, Sonia di Lemme, Roberta Fantozzi, Diego Centonze, Doriana Landi, Girolama Marfia, Elisabetta Signoriello, Giacomo Lus, Chiara Zecca, Claudio Gobbi, Rosa Iodice, Leonardo Malimpensa, Cinzia Cordioli, Diana Ferraro, Francesca Ruscica, Livia Pasquali, Anna Repice, Paolo Immovilli, Maria Teresa Ferrò, Simona Bonavita, Massimiliano Di Filippo, Gianmarco Abbadessa, Flora Govone, Maria Pia Sormani
BACKGROUND AND PURPOSE: Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment needed in years 3 and 4. However, comprehensive evidence regarding patient outcomes beyond the initial 24 months of cladribine treatment is limited. METHODS: This retrospective, multicenter study enrolled 204 patients with multiple sclerosis who had completed the 2-year course of cladribine treatment...
March 28, 2024: European Journal of Neurology